The PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. The three subtypes-termed PPAR-α, PPAR-δ and PPAR-γ-serve as lipid sensors in response to increased energy requirements 1 . PPARs are activated by lipids and fatty acid derivatives, and they perform essential functions in lipid homeostasis, glucose metabolism, energy production and cellular differentiation.
a r t i c l e s At the same time, the observation that HTT needs to be localized to the nucleus for HD pathogenesis to occur highlighted nuclear pathology as a potential early step in the neurotoxicity cascade 15 . N-terminal fragments of mutant HTT protein interfere with gene transcription in the early stages of the disease process (reviewed in ref. 16 ). We and others linked the mitochondrial dysfunction and metabolic defects in HD to the transcriptional dysregulation of PPARγ coactivator-1α (PGC-1α), a co-activator that controls a network of transcriptional programs that culminate in mitochondrial biogenesis and enhanced energy production [17] [18] [19] . The importance of PGC-1α for HD pathogenesis is underscored by the observation that PGC-1α overexpression in mouse models of HD (hereafter referred to as HD mice) is sufficient to rescue motor phenotypes, reduce accumulation of misfolded HTT protein in the CNS and ameliorate neurodegeneration 20 .
In an unbiased screen for HTT-interacting proteins, we found PPARs to be candidate interactors. We then evaluated the different PPARs and documented an interaction between PPAR-δ and HTT. We investigated the role of PPAR-δ repression in HD and determined that transcriptional dysregulation as a consequence of altered PPAR-δ function underlies mitochondrial dysfunction and neurodegeneration in HD. By directing expression of dominant-negative PPAR-δ to the CNS or specifically to MSNs in the striatum of HD mice, we demonstrated that expression of dominant-negative PPAR-δ is sufficient to produce motor phenotypes, neurodegeneration, mitochondrial defects and transcriptional abnormalities that parallel disease phenotypes in HD. In light of these results, we evaluated the PPAR-δ agonist KD3010 as a therapy for HD and found that KD3010 treatment could ameliorate HD phenotypes in transgenic mice and in striatal medium spiny-like neurons derived from induced pluripotent stem cells (iPSCs) from individuals with HD. Our findings offer novel insights into the pathogenesis of HD, provide evidence for an unexpectedly crucial role for PPAR-δ in maintaining neural health and highlight a promising therapeutic strategy for HD and related neurodegenerative disorders.
RESULTS

Huntingtin and PPAR- physically interact
To identify transcription factors that interact with HTT, we transfected HEK293 cells with a construct that encodes a GFP-tagged N-terminal human HTT protein containing 25 glutamines (GFP-HTT 25Q ), immunoprecipitated GFP-HTT 25Q and applied the immunoprecipitated material to a transcription factor binding-site array. This unbiased screen yielded PPAR-response element (PPRE)-binding proteins as candidate HTT-interacting proteins ( Supplementary  Fig. 1a ) and led us to examine whether HTT interacts with one of the PPARs. To test this hypothesis, we transiently cotransfected HEK293 cells with constructs encoding GFP-HTT 25Q , GFP-HTT 104Q or GFP alone and those encoding FLAG-tagged PPAR-α, PPAR-δ or PPAR-γ. After immunoprecipitating HTT using GFP-specific antibodies, we performed immunoblot analyses with a FLAG-specific antibody and detected PPAR-δ in immunoprecipitates from cells expressing GFP-HTT 25Q or GFP-HTT 104Q ; however, we found no evidence for an interaction between HTT and PPAR-α or between HTT and PPAR-γ ( Fig. 1a) . Quantification of the intensity of the PPAR-δ-specific band after GFP-HTT immunoprecipitation and immunoblot analysis indicated that the polyglutamine (polyQ)-tract expansion promotes greater interaction between PPAR-δ and HTT (Supplementary Fig. 1b) . PPAR-δ is the most abundantly expressed PPAR subtype in the CNS 8 ; however, its functional relevance in the CNS is not well defined. 
npg
To determine whether endogenous PPAR-δ and HTT interact, we performed coimmunoprecipitations from striatal-like cell lines derived from huntingtin knock-in mice (ST-Hdh), which feature equivalent expression of full-length mouse HTT protein with different polyQ tract lengths. After immunoprecipitating HTT with an antibody directed against its C terminus (Supplementary Fig. 1c ) and immunoblotting with a PPAR-δ-specific antibody, we found that PPAR-δ interacts with full-length HTT in ST-Hdh Q7/Q7 (in which both alleles of the knocked-in Htt gene at the Hdh locus have a polyQ tract of seven glutamines; considered to be wild type (not polyQ expanded)), polyQ-expanded heterozygous ST-Hdh Q7/Q111 and polyQ-expanded homozygous ST-Hdh Q111/Q111 cells ( Fig. 1b) . To establish whether this interaction occurs in the CNS under physiological conditions, we performed coimmunoprecipitation analyses on protein lysates made from the cortices of BAC-HD97 mice, a highly representative HD mouse model that features proper expression of full-length HTT protein 21 . We immunoprecipitated HTT, performed immunoblot analysis with a PPAR-δ-specific antibody and detected the PPAR-δ protein in the lysates from BAC-HD97 and nontransgenic mice ( Fig. 1c) . We then immunoprecipitated PPAR-δ and performed immunoblot analysis with an HTT-specific antibody; we observed both polyQ-expanded HTT (polyQ-HTT) and endogenous HTT protein in PPAR-δ immunoprecipitates from the cortices of BAC-HD97 mice and detected endogenous HTT in PPAR-δ immunoprecipitates from cortices of nontransgenic mice (Fig. 1d) . Finally, to determine the nature of the interaction, we performed in vitro transcription and translation of PPAR-δ and GFP-HTT Q25 (residues 1-171) and then did a pulldown with a GFP-specific antibody or an IgG-isotype control antibody. npg a r t i c l e s Immunoblot analysis of the pulled down material showed that PPARδ protein was specifically present in the immunoprecipitates obtained by using the GFP-specific antibody (Fig. 1e) . These findings indicate that PPAR-δ and HTT physically interact in the CNS.
Altered PPAR- transactivation contributes to mitochondrial dysfunction and neurotoxicity in HD
We evaluated the effect of polyQ-HTT on PPAR-δ transactivation by cotransfecting constructs expressing an N-terminal fragment of HTT (exons 1 and 2) and a 3×PPRE-luciferase reporter into HEK293 cells and noted a polyQ length-dependent inhibition of PPAR-δ transactivation after treatment with the PPAR-δ-selective agonist GW501516 ( Supplementary Fig. 2a ). We then measured PPAR-δ transactivation in ST-Hdh striatal-like cells; we found that PPAR-δ transactivation was significantly repressed (P < 0.05) in a polyQ length-dependent manner, that this repression could be partially rescued by expression of either PPAR-δ or PGC-1α and that repression could be fully rescued by expression of both PPAR-δ and PGC-1α ( Supplementary  Fig. 2b) . To examine the role of PPAR-δ-dependent transcriptional repression in neurons from HD mice, we repeated the transactivation assays in primary cortical neurons from BAC-HD97 mice (hereafter referred to as BAC-HD97 neurons) and observed significantly impaired PPAR-δ transactivation at baseline, after cotransfection with a construct encoding PPAR-δ or PGC-1α, and in response to cotransfection with constructs expressing PPAR-δ and PGC-1α ( Fig. 2a ). We measured mitochondrial membrane potential (MMP) and noted significantly reduced MMP in BAC-HD97 neurons ( Fig. 2b) . Notably, overexpression of PPAR-δ (via infection of cells with a PPAR-δ-encoding lentivirus) or treatment of cells with GW501516 rescued the mitochondrial membrane-polarization alterations in BAC-HD97 neurons, and the combination of PPAR-δ overexpression and GW501516 treatment resulted in the most robust effect ( Fig. 2b) . Activation of caspase-3, an enzymatic mediator of apoptosis, was elevated, and immunoreactivity of microtubule-associated protein (MAP) 2, which reflects neuron health, was reduced in BAC-HD97 neurons, as compared to that in primary cortical neurons from nontransgenic mice, indicating that HD neurons are more susceptible to cell death ( Fig. 2c) . We noted increased MAP2 staining and reduced caspase-3 activation in BAC-HD97 neurons that were transduced with the PPAR-δ-encoding lentivirus, in the presence of GW501516 ( Fig. 2c) . Increased PPAR-δ expression, GW501516 treatment or the combination of PPAR-δ expression and GW501516 treatment rescued cell death in BAC-HD97 neurons ( Fig. 2d) . Analysis of MAP2 immunoreactivity in BAC-HD97 neurons independently corroborated these results ( Supplementary Fig. 2c) .
We have previously shown that altered transcriptional activity of PGC-1α contributes to HD pathogenesis, with significant reductions in the expression of PGC-1α targets in mice or humans with HD 19 . Although the expression of PGC-1α is reduced in HD, the magnitude of the decrease cannot fully account for the transcriptional alterations documented in HD, indicating that a PGC-1α-dependent transcription factor could be responsible for the transcriptional dysregulation. Because PPAR-δ and HTT physically interact in the CNS and because specific PPAR-δ target genes exhibit reduced expression in the striatum npg from BAC-HD97 mice, we postulated that impaired PPAR-δ function accounts for altered PGC-1α transcriptional activity in HD. Gene set analysis of Affymetrix U133A/B microarray expression data from the striata of individuals with HD revealed significant alterations in 12 of 16 principal PPAR-δ target genes (P < 10 −4 , chi-squared test; Supplementary Fig. 3a) , consistent with this hypothesis.
Physical interaction of polyQ-HTT with PPAR- promotes HD neurotoxicity
To determine the physiological relevance of the interaction between PPAR-δ and HTT, we examined striatal sections from HD N171 82Q transgenic mice (in which the HTT N-terminal fragment has 82 glutamines) and observed colocalization of polyQ-HTT protein with PPAR-δ ( Supplementary Fig. 3b ). To test whether disruption of this interaction could prevent polyQ-HTT-dependent neurotoxicity, we created expression constructs encoding PPAR-δ with deletions of different domains (Supplementary Fig. 4a ). We cotransfected HEK293 cells with expression constructs encoding GFP-tagged HTT or domain-deleted PPAR-δ, performed co-immunoprecipitation analyses and mapped the HTT interaction site to the D domain (hinge region) of PPAR-δ (Supplementary Fig. 4b) .
To determine whether the physical interaction between polyQ-HTT and PPAR-δ is necessary for neurotoxicity, we co-expressed different PPAR-δ deletion mutants in combination with full-length PPAR-δ in ST-Hdh Q111/Q111 striatallike cells. Although co-expression of PPAR-δ lacking either the A-C domains or the E-F domains prevented polyQ-HTT-mediated transcriptional repression, mitochondrial membrane depolarization and cell death, co-expression of PPAR-δ lacking the D-F domains did not rescue any of these neurotoxicity phenotypes (Supplementary Fig. 5) .
These findings indicate that the PPAR-δ deletion constructs that specifically retain the D domain can compete for binding to the mutant HTT and that this binding is sufficient to blunt polyQ-HTT-mediated neurotoxicity, thus underscoring the importance of the PPAR-δ-mutant HTT interaction for HD pathology.
Previous studies have implicated PPAR-γ-mediated transcriptional alterations in HD pathogenesis [22] [23] [24] . To examine the potential contribution of PPAR-α or PPAR-γ dysfunction to polyQ-HTT-mediated neurotoxicity, we surveyed PPAR expression in the CNS. Immunohistochemical analysis of sections from the cortices of control mice revealed prominent neuronal expression of PPAR-δ, modest neuronal expression of PPAR-α and barely detectable neuronal expression of PPAR-γ ( Fig. 2e) . In the cortex, striatum and cerebellum of BAC-HD97 mice and nontransgenic littermates, we observed prominent neuronal expression of PPAR-δ and limited expression of PPAR-α or PPAR-γ ( Supplementary Fig. 6 ). These findings were corroborated by immunoblot analyses of cortical lysates, cortical neurons, cerebellar lysates and cerebellar granule neurons from BAC-HD97 and nontransgenic mice ( Supplementary Fig. 7a-d) .
To directly determine the contributions of the different PPARs to polyQ-HTT-mediated neurotoxicity, we cultured primary cortical neurons from BAC-HD97 mice and monitored cell death after knocking down expression of Ppard, Ppara or Pparg (which encode PPAR-δ, PPAR-α and PPAR-γ, respectively) or after agonist-mediated activation of each PPAR. Cell death was increased in BAC-HD97 neurons in which Ppard expression was silenced by using short hairpin RNAs (shRNAs), whereas knockdown of Ppara or Pparg did not affect cell death (Fig. 2f) . Similarly, treatment of cells with a PPAR-δ agonist reduced cell death, as compared to BAC-HD97 neurons treated with an agonist to PPAR-α or to PPAR-γ ( Fig. 2f) .
To evaluate the contribution of PPAR-δ-dependent transcriptional alterations to HD pathogenesis in vivo, we measured the expression of 11 PPAR-δ target genes in the striatum of BAC-HD97 transgenic mice and noted reduced expression for all of the tested PPAR-δ target genes (Supplementary Fig. 7e ). RT-PCR analysis confirmed significant reductions in the expression levels of PPAR-δ targets in ST-Hdh Q111/Q111 striatal-like cells, as compared to ST-Hdh Q7/Q7 cells (Fig. 3a) . We then performed chromatin immunoprecipitation and found that PPAR-δ occupancy is reduced at the promoters of its target a r t i c l e s genes in ST-Hdh Q111/Q111 striatal-like cells (Fig. 3a) , suggesting that PPAR-δ binding to target promoters is prevented after its interaction with polyQ-HTT.
Dominant-negative PPAR- expression in the CNS induces neurological disease
To determine whether impaired PPAR-δ transactivation function is sufficient to elicit neurodegeneration in vivo, we derived a conditional transgenic Ppard construct that encodes PPAR-δ with a single amino acid mutation, a substitution of proline for glutamate at residue 411 (Ppard E411P ) (Supplementary Fig. 8a) . The Ppard E411P mutation results in the inhibition of PPAR-δ transactivation in a dominantnegative manner 25, 26 . After generating transgenic mice for Ppard E411P such that a combined β-actin promoter-cytomegalovirus (CMV) enhancer and a STOP cassette, flanked by loxP sites, is placed 5′ to the Ppard E411P cDNA (hereafter referred to as CAGGS-floxed STOP-Ppard E411P mice), we evaluated these mice for signs of systemic or neurological phenotypes and did not detect any evidence of abnormality. We then crossed these mice with mice expressing the Cre recombinase under the control of the CMV promoter (CMV-Cre driver mice) to permit widespread expression of Ppard E411P . Similarly to Ppard-knockout mice 27 , we found that ubiquitous expression of the PPAR-δ E411P protein causes prenatal lethality. We next crossed the CAGGS-floxed STOP-Ppard E411P mice with Nestin-Cre mice to obtain double-transgenic Nestin-Cre;Ppard E411P mice, in which the Nestin-Cre driver promotes expression of the Cre recombinase throughout the neural lineage 28 . PPARδ E411P protein was expressed at 1.5-to 2-fold the levels of the endogenous PPAR-δ protein.
Characterization of Nestin-Cre;Ppard E411P mice, in comparison to single-transgenic Nestin-Cre or CAGGS-floxed STOP-Ppard E411P mice, indicated that Nestin-Cre;Ppard E411P double-transgenic mice appear smaller by 4-6 months of age, such that by 8 months of age they weigh less than littermate controls (Fig. 3b) . Phenotype evaluation using a neurological examination screening tool 29 revealed that Nestin-Cre;Ppard E411P mice suffer prominent motor abnormalities by 8 months of age ( Fig. 3c-e) . Testing of the Nestin-Cre;Ppard E411P mice on an accelerating rotarod confirmed motor impairment (Fig. 3f) , and stride-length analysis and grip-strength testing provided further evidence for motor abnormalities (Fig. 3g) . We also evaluated learning and memory in Nestin-Cre;Ppard E411P mice and documented reduced novel-object recognition and reduced novel-environment exploration (Supplementary Fig. 8b-d) .
Ultrastructural analysis of Nestin-Cre;Ppard E411P mice revealed that mitochondria in the striatum appear smaller in size (Fig. 3h) , in agreement with previous studies of HD 30, 31 , as the mitochondrial area and perimeter in the cortex and striatum were reduced (Fig. 3i) . To evaluate metabolic function, we measured the activities of mitochondrial complexes. Although the activities of mitochondrial complex I and complex II from Nestin-Cre;Ppard E411P and control mice were similar, the activities of mitochondrial complex IV and complex V were reduced in the striatum of Nestin-Cre;Ppard E411P mice (Supplementary Fig. 9a-d) , and the overall ATP concentration was reduced in the striatum and cortex (Fig. 3j) . Quantitative PCR analysis of mitochondrial and nuclear genomic DNA content corroborated the abnormalities in mitochondrial bioenergetics in the Nestin-Cre;Ppard E411P mice (Supplementary Fig. 9e ).
Brain size in adult Nestin-Cre;Ppard E411P mice was markedly reduced in comparison to that of littermate controls (Fig. 4a) . Comparable reductions in the volumes of the cortex and the basal ganglia were noted in the Nestin-Cre;Ppard E411P mice (Fig. 4b,c) . Staining the brain sections of Nestin-Cre;Ppard E411P mice for the neuronal marker NeuN revealed reduced neuron numbers (Fig. 4d) . This was paralleled by a reduction in tyrosine hydroxylase (TH)-positive dopaminergic neurons in the substantia nigra (Fig. 4e) , decreased MAP2 immunostaining in the cortex and hippocampus (Fig. 4f) , and reactive gliosis, as assessed by glial fibrillary acidic protein (GFAP)specific immunostaining in the brains of Nestin-Cre;Ppard E411P mice (Fig. 4g) . Thus, mice expressing a dominant-negative version of PPAR-δ in the CNS develop striking neurological abnormalities in the context of profound neurodegeneration. 
Dominant-negative PPAR- expression in the striatum induces HD-like phenotypes
To assess the effect of dominant-negative PPAR-δ-dependent transcriptional interference in the striatum only, we obtained the Rgs9-Cre mouse line, which restricts expression of Cre recombinase to striatal MSNs 32 , and derived double-transgenic Rgs9-Cre;Ppard E411P mice. Although the Rgs9-Cre;Ppard E411P mice are of similar size and weight as gender-matched littermate controls, the Rgs9-Cre;Ppard E411P mice develop motor abnormalities, as assessed by composite neurological examination 29 , rotarod analysis and grip-strength testing ( Fig. 5a-e ). Neuropathological examination of Rgs9-Cre;Ppard E411P mice revealed evidence for decreased numbers of striatal neurons (Fig. 5f,g) , owing to a reduction in parvalbumin-immunoreactive neurons, as acetylcholinesterase-positive neurons were spared (Supplementary Fig. 10 ). This pattern is consistent with striatal neuron loss observed in individuals with HD 33, 34 . Because the CAGGSfloxed STOP-Ppard E411P transgenic crosses with the Nestin-Cre and Rgs9-Cre driver lines yielded distinct patterns of neurodegeneration that reflect Cre recombinase expression, the observed phenotypes cannot be attributed to insertional mutagenesis. Another defining feature of HD pathogenesis is transcriptional abnormalities 16 . We used RNA-seq analysis to assess the striatal transcriptomes of Nestin-Cre;Ppard E411P mice and found that 583 genes in the striatum from these mice were altered in their expression, as compared to littermate controls. We performed Gene Ontology database analysis on this 583-gene set, identified altered Biofunctions pathways and represented these pathways in proportion to the percentage of the total number of genes whose expression was altered for each significantly perturbed pathway (Fig. 5h) . To determine whether the transcriptomic changes found in the striatum of Nestin-Cre;Ppard E411P mice overlap with the changes observed in brains from individuals with HD, we performed Gene Ontology database analysis on the genes whose expression was altered in the caudate of individuals with HD 35 , and we represented the detected Biofunctions pathways in proportion to the percentage of the total number of genes whose expression was altered for each pathway ( Fig. 5h) . We ascribed an order to the altered Biofunctions pathways for the human HD caudate transcriptome and the Nestin-Cre; Ppard E411P striatum transcriptome ( Supplementary Table 1 ) and observed nearly identical Biofunctions pathway rankings (P < 10 −11 ). To validate gene expression alterations identified by RNA-seq analysis, we performed qRT-PCR analysis on striatal RNAs from Nestin-Cre;Ppard E411P mice for 11 genes, and documented altered expression for 10 of the 11 tested genes, all in the predicted direction ( Supplementary Fig. 11a ). Finally, to assess the specificity of polyQ-HTT repression of PPAR-δ, we performed assays with the 3×PPRE reporter in HEK293 cells transfected with constructs that encode ataxin-7 10Q or ataxin-7 92Q -the protein variants associated with a different CAG polyQ-repeat disorder, spinocerebellar ataxia type 7. We found that cells expressing ataxin-7 92Q did not repress PPAR-δ transactivation (Supplementary Fig. 11b ).
The PPAR- agonist KD3010 rescues neurological phenotypes and neurodegeneration PPAR-δ-selective compounds have been identified as potential therapies for type 2 diabetes and metabolic syndrome 36 . KD3010 ((S)-4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1sulfonyl]-indan-2-carboxylic acid tosylate) is a highly selective and potent PPAR-δ agonist 37 . Treatment with KD3010 (in the low-nanomolar range) rescued dominant-negative PPAR-δ-mediated transcriptional repression and mitochondrial dysfunction in BAC-HD97 neurons and could prevent cell death in primary cortical neurons transfected with a 586-residue N-terminal HTT fragment containing 82 glutamines (Supplementary Fig. 12a-c) . Intraperitoneal (i.p.) injection of KD3010 (15 mg per kg of body weight (mg/kg)) into C57BL/6J mice resulted in a ratio of KD3010 in the brain to KD3010 in the plasma of ~10% at 2-to 24-h after injection ( Supplementary  Table 2 ). To test whether KD3010 treatment could promote PPAR-δ transactivation in the brains of living mice, we injected KD3010 at 50 mg/kg per day (mg/kg/d) and found that this treatment induced the expression of PPAR-δ target genes (Supplementary Fig. 12d ). KD3010 treatment did not cause weight loss or visible side effects, d npg a r t i c l e s and we did not find any evidence of organ toxicity. Hence, KD3010 treatment at 50 mg/kg/d is tolerated in mice and can promote the PPAR-δ transactivation function in the mammalian CNS. The HD N171 82Q mouse model recapitulates HD-like motor phenotypes and neurodegeneration within a time frame of 5-6 months 38 . Beginning at 6 weeks of age, HD mice were injected with either 50 mg/kg/d of KD3010 or vehicle, five times per week. Of note, we adhered to recommended preclinical trial guidelines, which are intended to avoid spurious results 39, 40 . We tracked the progression of the disease phenotypes in vehicle-treated and agonist-treated HD mice by performing composite neurological examination 29 , rotarod analysis and grip-strength testing at 4-week intervals. KD3010 treatment attenuated neurological dysfunction and improved motor function in HD mice, as compared to vehicle-treated controls (Fig. 6a,b and Supplementary  Fig. 12e-g) . Striatal choline acetyltransferase (ChAT) levels, which are used as a measure of striatal interneuron dysfunction in HD 33 , were increased, aggregated HTT protein was reduced and striatal volume was maintained in KD3010-treated HD mice ( Fig. 6c and Supplementary  Fig. 13 ). In addition to attenuating neurological phenotypes and neurodegeneration, KD3010 treatment yielded a 16% extension in mean lifespan of HD mice (Fig. 6d) . Finally, we differentiated iPSCs from individuals with HD into striatal medium spiny-like neurons and treated these human HD medium spiny-like neurons with KD3010. Whereas treatment with the inactive enantiomer of KD3010 did not offer any protection from cell death, treatment with KD3010 rescued cell death in neurons derived from individuals with HD ( Fig. 6e) .
DISCUSSION
Here we document PPAR-δ-mediated transcriptional interference as a cause of the bioenergetics defects and mitochondrial abnormalities in HD. In addition to demonstrating that HTT represses PPAR-δ transactivation in an interaction-dependent manner to yield mitochondrial defects and neurotoxicity in a variety of model systems, we generated transgenic mice expressing dominant-negative PPARδ to recapitulate HD-like behavioral, metabolic and transcriptional phenotypes. Because interfering with PPAR-δ function in mice can phenocopy HD, our findings implicate PPAR-δ dysregulation as a key node in the HD pathogenic cascade.
Of the three PPARs, the least-studied member of this family is PPAR-δ. We found that treatment with a PPAR-δ-selective agonist evoked a robust response in transactivation assays, and we demonstrated that PPAR-δ could elicit neuroprotection in primary neurons from mouse models of HD. To clarify the role of PPAR-δ with respect to that of PPAR-α and PPAR-γ, we modulated each PPAR individually using shRNA knockdown or agonist treatment and found that only PPAR-δ modulation yielded highly significant effects on HD neurotoxicity. We documented that PPAR-δ is much more highly expressed than PPAR-α or PPAR-γ in neurons of the cortex and striatum, in agreement with previous work 41 . Although studies have shown that treatment with a PPAR-γ agonist can ameliorate disease phenotypes in HD 22, 42, 43 , the beneficial effects of PPAR-γ-agonist therapy probably stem from improved function in peripheral tissues, hypothalamic neurons and non-neural CNS cells 41 . Because our studies suggested an important role for PPAR-δ in neural function, we generated lines of conditional transgenic PPAR-δ mice and directed expression of dominant-negative PPAR-δ to neurons throughout the CNS or just to striatal MSNs. These experiments revealed that PPAR-δ is necessary for normal neural function, as profound neurological and neurodegenerative phenotypes emerged in mice expressing dominant-negative PPAR-δ in neural lineages.
Our findings thus identify neurons as a cell type in which PPAR-δ is essential for homeostasis.
We theorized that if impaired PPAR-δ function is contributing to HD pathogenesis, then an attractive treatment option would be to agonize PPAR-δ. Of the various possible PPAR-δ agonists, we opted to use KD3010, as this PPAR-δ agonist is potent and specific, crosses the blood-brain barrier and was approved for use in humans in a Phase 1b metabolic disease safety trial in which no incidences of side effects were reported. We performed a preclinical trial of KD3010 treatment in HD N171 82Q transgenic mice and observed compelling evidence for therapeutic efficacy. To further evaluate KD3010 as a treatment for HD, we tested KD3010 in striatal medium spiny-like neurons derived from human iPSCs from individuals with HD and documented robust neuroprotection in the nanomolar range. Our findings strongly suggest that repurposing PPAR-δ agonists that are capable of crossing the blood-brain barrier is a viable treatment strategy for HD and that treatment with KD3010 should be pursued as a lead. Because mitochondrial dysfunction and transcription interference with PGC-1α, the co-activator for PPAR-δ, are recognized features of Parkinson's disease (PD) pathogenesis 44, 45 and because we observed marked loss of TH + dopaminergic neurons in the substantia nigra of dominant-negative PPAR-δ conditional transgenic mice, we note that PPAR-δ-agonist therapy should also be considered as a treatment for PD.
Another facet of PPAR-δ biology with relevance to therapy development for neurodegenerative disease is that PPAR-δ forms a heterodimer with the retinoid X receptor (RXR), and RXR agonists are capable of promoting PPAR-δ transactivation 46 . Bexarotene, a synthetic drug approved for use in humans, is structurally similar to retinoic acid compounds that are known endogenous RXR ligands. One provocative study reported that administration of bexarotene to a mouse model of Alzheimer's disease (AD) yielded dramatic improvements in cognitive, social and olfactory deficits, accompanied by improved neural circuit function and enhanced clearance of soluble Aβ oligomers 47 . Because PPAR-δ is highly expressed in neurons of the CNS 8 and because bexarotene can potently activate PPAR-δ, our results indicate that enhanced PPAR-δ activation could be contributing to bexarotene-mediated neuroprotection in AD 47, 48 .
Because the PPAR-δ-PGC-1α pathway promotes the expression of genes that drive high-level energy production and insure protein and organelle quality control, the neuroprotective effects of agonizing this pathway probably stem from boosting neuronal bioenergetics and proteostasis. HD, PD and AD are all late-onset disorders, implying that a decline in the function of crucial homeostatic pathways with age is a central factor in the development of clinical disease. In HD, this view is all the more relevant, as affected individuals express the mutant, disease-associated protein from the time of conception, yet they can live for more than five or even six decades without obvious symptoms. It seems reasonable to propose that activation of pathways promoting energy production (which is always under high demand in neurons and CNS cells) and supporting protein and organelle quality control (which constitutes a major challenge for neurons and other CNS cell types) may stave off cellular decompensation in the face of proteotoxic stress during this long prodromal phase. Thus, therapies directed at boosting PPAR-δ function could have broad applicability for a wide range of neurodegenerative diseases.
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